Jane Street
INDV icon

Jane Street’s Indivior Pharmaceuticals INDV Stock Holding History

Jane Street’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.03M Buy
33,800
+11,700
+53% +$386K ﹤0.01% 6438
2025
Q4 		$793K Buy
+22,100
New +$675K ﹤0.01% 6637

Other funds holding INDV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Jane Street's INDV Position: Q4 2025 in Review

Jane Street sold out of Indivior Pharmaceuticals (INDV) in Q4 2025, closing a stake of 678,727 shares — an estimated $20.7M sold.

Jane Street first reported a position in INDV in Q1 2024 and held it in 6 quarters. The position peaked at $16.4M in Q3 2025. 259 funds tracked by Wall St. Rank hold INDV as of Q4 2025.

  • Jane Street reported no remaining Indivior Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Jane Street sold 678,727 Indivior Pharmaceuticals shares in Q4 2025, an estimated $20.7M.
  • Jane Street first reported a position in Indivior Pharmaceuticals in Q1 2024 and held it in 6 quarters.
  • Jane Street's Indivior Pharmaceuticals position peaked at $16.4M in Q3 2025.
  • 259 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q4 2025.

Based on Jane Street's 13F filing for Q4 2025, filed 12 Feb 2026.